Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
29,494
Total Claims
$1.8M
Drug Cost
881
Beneficiaries
$1,989
Cost/Patient
Risk Score Breakdown 26/100
Score components are additive. Read full methodology
Peer Comparison vs. 7,389 General Practice providers
-92%
Opioid rate vs peers
0.2% vs 2.5% avg
+76%
Cost per patient vs peers
$1,989 vs $1,128 avg
+63%
Brand preference vs peers
13.7% vs 8.4% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
0.2%
Opioid Rate
59
Opioid Claims
$254
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 3,987 claims · $1.4M
Generic: 25,083 claims · $319K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dapagliflozin Propanediol | 337 | $207K |
| Dapaglifloz Propaned/Metformin | 218 | $154K |
| Sitagliptin Phos/Metformin Hcl | 57 | $85K |
| Insulin Glargine,hum.Rec.Anlog | 221 | $82K |
| Dulaglutide | 84 | $80K |
| Apixaban | 133 | $70K |
| Semaglutide | 52 | $56K |
| Levothyroxine Sodium | 1,027 | $55K |
| Insulin Lispro | 110 | $42K |
| Insulin Nph Human Isophane | 126 | $41K |
| Empagliflozin | 37 | $40K |
| Budesonide/Formoterol Fumarate | 98 | $38K |
| Insulin Nph Hum/Reg Insulin Hm | 115 | $37K |
| Insulin Regular, Human | 127 | $32K |
| Sitagliptin Phos/Metformin Hcl | 29 | $29K |
Prescribing Profile
Patient Profile
73
Avg Age
61%
Female
1.85
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data